Contact Us 联系我们
Contact Us 联系我们
Contact Us 联系我们

Investors

Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements



DateTitle
14/11/2019Race reveals new strategy for cancer drug BisantreneDownload
24/10/2019Appendix 3Y-Dr Daniel TillettDownload
17/10/2019Notice of Annual General Meeting/Proxy FormDownload
17/10/2019Annual Report to shareholdersDownload
17/10/2019Appendix 4C - quarterlyDownload
14/10/2019Appendix 3Y-Chris NtoumenopoulosDownload
14/10/2019Change in substantial holdingDownload
14/10/2019Appendix 3BDownload
14/10/2019Cleansing NoticeDownload
14/10/2019Appendix 3Y-Dr Bill GarnerDownload
1  2  3  4  5  6  

ASX: RAC

Price

Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2019 Race Oncology. Website By Multiplier